RecruitingNCT07226115

Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer

Splicing-Based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer (SPLICE)


Sponsor

City of Hope Medical Center

Enrollment

200 participants

Start Date

Jun 21, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Although adjuvant chemotherapy improves survival after curative resection, its efficacy varies widely among patients. The absence of reliable predictive biomarkers often leads to overtreatment or undertreatment. This study aims to develop a machine learning-based predictive model for adjuvant chemotherapy response using tumor-derived alternative splicing signatures. By integrating RNA-seq data, splicing isoform and clinical outcomes, this study seeks to identify molecular predictors of treatment response and recurrence risk after surgery.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria5

  • Histologically confirmed stage II-III colorectal cancer (TNM classification, 8th edition)
  • Received standard adjuvant chemotherapy after curative resection
  • Availability of tumor tissue (FFPE or frozen) before chemotherapy
  • Sufficient clinical data for outcome analysis (recurrence, survival)
  • Age 18-80 years Stage

Exclusion Criteria2

  • Inflammatory bowel disease
  • Inadequate RNA quality or lack of consent

Interventions

OTHERSPLICE

A panel of RNA splicing isoform, whose level is tested in tissue samples derived from the primary tumor.


Locations(1)

City of Hope Medical Center

Duarte, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07226115


Related Trials